OnPoint Analytics
Retaining the right expert is often one of the most important decisions made in litigating a case. You need an expert witness with impeccable credentials, deep experience in the domain space, and superb communication skills. Behind that expert, you need a team to match. Together, they must function quickly and efficiently, responding to the almost limitless complexities of litigation. They need to see all the angles before delivering the right solution.
Learn more About Us , explore our Service Areas , and meet our diverse panel of Experts from across the country.
News
Our clients need to move rapidly and so do we. Each day is complete with its own series of challenges and accomplishments—a few of these are gathered in our News section.
On May 5, 2020, U.S. District Judge Nina Gershon for the Eastern District of New York certified a class of End-Payor Plaintiffs (EPPs) in the antitrust...Read More
OnPoint Analytics is pleased to introduce the latest addition to our team of experts: Professor Daniel Hamermesh. Professor Hamermesh is Distinguished Scholar, Barnard College; Sue Killam...Read More
OnPoint Analytics is pleased to introduce the latest addition to our team of experts: Professor Mark R. Killingsworth. Dr. Killingsworth is a Professor in the Department...Read More
On January 6, 2020, the day trial was set to start, Class Plaintiffs reached an agreement with Defendants Warner Chilcott and Watson Pharmaceuticals to end the...Read More
Analysis performed by OnPoint expert Dr. John Connor helped secure a settlement for Winn-Dixie in its dispute with major dairy cooperatives concerning the Cooperatives Working Together...Read More
OnPoint is pleased to announce that Dr. Gareth Macartney starts 2020 as OnPoint’s new Chief Executive Officer. Dr. Macartney has been with OnPoint for eleven years....Read More
Biosimilars Tracker
More than a decade after its enactment, the Biologics Price Competition and Innovation Act is finally transforming the economic and therapeutic landscape for some of the world’s most important drugs. Having struggled with legal and practical implementation, the FDA is approving biosimilars designed as lower cost substitutes for major biologics. OnPoint’s Tracker collects current information on approved biosimilars, their cost and formulary status.
Visit OnPoint’s Biosimilars Tracker to see the latest information you need to know about currently approved biosimilars and their availability in the United States.
9 Reference Products29 Approved Biosimilars